REGENXBIO Inc. (Nasdaq:RGNX) today announced that Dimension Therapeutics, Inc. (Nasdaq:DMTX) notified REGENXBIO that it has determined that it has received a “superior proposal” as defined in the merger agreement under which REGENXBIO would have acquired Dimension in an all-stock transaction for an implied value of approximately $3.41 per share based on the closing stock price of REGENXBIO stock on August 24, 2017.
CureSearch for Children’s Cancer announced the application launch for a $2 million to $5 million (USD) Catapult Impact Fund Award opportunity. The award will support the advancement of clinical research to improve outcomes for pediatric cancer patients.
Johns Hopkins Technology Ventures kicked off its inaugural cohort of healthcare startups last month with a focus on connected health and fitness. Called M-1 Ventures, a reference to first-year medical students, the accelerator represents a change of strategy for cultivating early stage companies. Although Johns Hopkins previously collaborated with Dreamit Ventures, it was interested in developing an accelerator on its own. To that end it formed regional alliances with the University of Maryland, Village Capital., and the family office of Baltimore-based Under Armour CEO and Chairman Kevin Plank — Plank Industries.
Sisu Global Health is entering product launch phase in a pair of African countries.
The company recently received regulatory clearance to sell its blood transfusion device in Kenya and Ghana, CEO Carolyn Yarina said.
Protenus, the health care industry’s most robust, analytics-driven solution for detecting inappropriate activity in the electronic health record, is excited to announce that its Co-Founder and President, Robert Lord, has been selected as a New America Cybersecurity Policy Fellow for the 2017-2018 cohort. This fellowship brings together the world’s top cybersecurity leaders from private industry, academia, journalism, the public sector, and the military to envision and build the future of cybersecurity.
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its recently submitted supplemental New Drug Application (sNDA) for lubiprostone (AMITIZA®) in children aged 6 to 17 years with pediatric functional constipation. The filing has received Priority Review designation from the FDA.
Baltimore has the potential to be a city that is truly hospitable to small business growth, with all the economic benefits of jobs and tax revenue such growth would bring. But for new and established small businesses to thrive, the city needs a financing system with capacity to meet their needs.
Capital is certainly not the only ingredient necessary for successful business growth, but it is a critical input. If companies lack access to appropriate types of capital at critical stages of growth, they are likely to never take off and achieve scale, or even worse, to go out of business or leave Baltimore and relocate where financial support is more readily available, depriving the local economy of jobs and economic growth.
The Washington Business Journal’s annual Innovation Awards honor 15 Greater Washington companies, agencies and teams working to keep the metro on the cutting edge in tech, health care, cybersecurity and more.
Health Canada has approved the probiotic Visbiome as a Natural Health Product for treating symptoms of irritable bowel syndrome in adults and children aged older than 5 years, the manufacturer announced.
From catching Pokémon in the real world to donning a virtual reality headset to see and feel what it was like to scale the Berlin Wall before its fall, advancements in immersive media have set the stage for the next digital revolution. The University of Maryland will lead this revolution with the launch of the Mixed/Augmented/Virtual Reality Innovation Center, called MAVRIC, which has been awarded a $500,000 grant from the U.S. Department of Commerce Economic Development Administration (EDA).
